ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the ...

Enhertu is forecast to retain its dominant market position in the ADC landscape and reach global sales of $11.2bn by 2030.

One of your patients might be eligible to enroll in a clinical trial currently recruiting people with breast cancer.

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

Despite positive KEYNOTE-811 results, Merck & Co’s position in this setting is not devoid of threats from other competitors.

New research suggests that a majority of patients with endometrial cancer may have tumors with a HER2 score of 2+ or higher.

The recent GST cut on cancer drugs could mean significant cost reductions for cancer treatment in India. Read to know how it ...

Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...